Compare Logitech International SA (LOGI) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Natera Inc. Common Stock — how do they compare? Logitech International SA trades at $101.12 (market cap $14.62B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 3.9× Logitech International SA's market cap, and Logitech International SA pays a 1.61% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Logitech International SA for 92 Days and Natera Inc. Common Stock for 0 Days on average.
| LOGI | NTRA | |
|---|---|---|
Market Cap | $14.62B | $57.03B |
Volume | 811,529 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $126.69 | $425.64 |
52-Week Low | $85.84 | $179.42 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $12.95B | $56.18B |
Dividend Yield | 1.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $101.16, up 2.88% today, with a bullish technical signal from moving averages and support at $101. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.85 beating expectations of $1.26. Fundamentals show robust profitability with a net margin of 16.28% and ROE of 35.29%, while recent news highlights new product launches and partnerships.
The outlook is positive with a consensus price target of $107, offering ~6% upside. Key opportunities include product innovation and market share gains, but risks involve chip shortages and competitive pressures. Analyst sentiment is mixed with 26% buy ratings, suggesting cautious optimism amid execution challenges.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
